Foundation Medicine
Présence
Roche fait partie des...
- Forbes Global 2000 (#76);
- Fortune 500 Europe (#38);
- Global Fortune 500 (#184);
- Russell 3000;
- Stoxx 600;
- Swiss market index.
Roche est une société cotée sous le symbole boursier ROG (CH).
Roche a une présence directe dans 23 pays.Roche a 39 filiales dont Cenexi, Chugai Pharmaceutical et Flatiron Health.
Elles sont en:
- Pharmacie70%
- Biotechnologie25%
- Autre5%
Acquisition, funding and merger involving Roche.
- Roche has announced the acquisition of Carmot Therapeutics (publié le 7 décembre 2023).
Dirigeants
Voir l'organigramme avec ses 11 principaux dirigeants
Biographies les plus recherchées chez Foundation Medicine
- Dan Malarek, Chief Executive Officer
- Lucas Dennis, Senior Vice President and Head of Research and Deve...
- Michael Kling, Chief Technology Officer
Changements de dirigeants chez Foundation Medicine
- Dan Malarek, a rejoint l'entreprise comme Chief Executive Officer (publié le 14 décembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Foundation Medicine.
Biotechnologie
Roche a 2 275 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Histogen has filed for bankruptcy protection (publié le 19 avril 2024).
- Bruker has announced the acquisition of NanoString Technologies (publié le 18 avril 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publié le 16 avril 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Foundation Medicine
- Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
- Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
- Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
- AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
- U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer
- Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Foundation Medicine
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer | Fou
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Foundation Medicine
- Foundation Medicine sur Wikipédia, Google News & Yahoo Finance en 1-click
- Foundation Medicine sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Dan Malarek 
Appelez Foundation Medicine au +1 617...
